Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer

This study has been completed.
Sponsor:
Collaborators:
Schering-Plough
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00068575
First received: September 10, 2003
Last updated: February 13, 2012
Last verified: February 2012

September 10, 2003
February 13, 2012
May 2002
December 2010   (final data collection date for primary outcome measure)
Median Overall Survival (OS) [ Time Frame: Participants followed till disease progression or death (approximately 6 years) ] [ Designated as safety issue: No ]
Overall Survival defined overall survival time, measured from date of tissue diagnosis till disease progression or death.
Not Provided
Complete list of historical versions of study NCT00068575 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
A Phase II Trial of Pancreaticoduodenectomy Plus Postoperative Cisplatin, Interferon Alfa-2b, and 5-FU Combined With Radiation Treatment for Patients With Resected Pancreatic Adenocarcinoma

RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as interferon alfa may interfere with the growth of the tumor cells and slow the growth of cancer. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and interferon alfa with radiation therapy after surgery may kill any remaining tumor cells.

PURPOSE: This phase II trial is studying how well giving cisplatin, fluorouracil, and interferon alfa together with radiation therapy works in treating patients who have undergone surgery for stage I, stage II, or stage III pancreatic cancer.

OBJECTIVES:

Primary

  • Determine the overall survival of patients with previously resected pancreatic adenocarcinoma treated with postoperative cisplatin, interferon alfa, fluorouracil, and concurrent radiotherapy.
  • Determine the toxic effects of this regimen in these patients.

Secondary

  • Determine the disease-specific, biochemical failure-free, and symptom/treatment-free survival of patients treated with this regimen.
  • Determine the quality of life of patients treated with this regimen.

OUTLINE:

  • Chemoradiotherapy: Patients receive fluorouracil intravenous (IV) continuously and interferon alfa subcutaneously (SQ) 3 times per week (total of 17 doses) on days 1-19 and 29-45 and cisplatin IV over 6 hours on days 1, 8, 15, 29, 36 and 43. Patients also undergo concurrent radiotherapy once daily, 5 days a week in weeks 1-3 and 5-7 (28 fractions).
  • Post-chemoradiotherapy fluorouracil: Patients receive fluorouracil IV continuously on days 71-108 and 127-168.

PROJECTED ACCRUAL: A total of 44 patients will be accrued for this study.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Pancreatic Cancer
  • Biological: Recombinant Interferon Alfa
    3 million units subcutaneously every other day (Monday, Wednesday and Friday) during Days 1-19 and 29-45, for 6 1/2 weeks totaling 17 doses.
    Other Names:
    • Interferon alfa-2b
    • IFN
  • Drug: Cisplatin
    30 mg/m^2 IV over 60 minutes on days 1, 8, 15, 29, 36, 43 - weekly for total 6 doses, during 5 1/2 weeks radiation therapy.
    Other Names:
    • Platinol-AQ
    • Platinol
    • CDDP
  • Drug: Fluorouracil
    175 mg/m^2/day continuous infusion over 6 1/2 weeks for total 3 courses: Days 1-19 and 29-45, Days 71-108 and Days 127-168.
    Other Names:
    • 5-fluorouracil
    • Adrucil
    • Efudex
  • Radiation: Radiation Therapy
    External beam radiation on days 1-19 and days 29-45, 9 day treatment break on day 20.
    Other Names:
    • RT
    • Radiatherapy
Experimental: Postoperative Chemoradiation Regimen
Postoperative Cisplatin 30 mg/m^2 intravenous (IV) weekly for 6 doses, Interferon Alfa-2b 3 million units subcutaneous (SQ) on Monday, Wednesday and Friday days 1-19 and 29-45 for 17 total doses, and 5-fluorouracil (5-FU) 175 mg/m2/day by continuous intravenous infusion days 1-19 and 29-45 with concurrent Radiation Treatment.
Interventions:
  • Biological: Recombinant Interferon Alfa
  • Drug: Cisplatin
  • Drug: Fluorouracil
  • Radiation: Radiation Therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
29
December 2010
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Biopsy proven completely resected (R0 or R1) pancreatic adenocarcinoma of the pancreatic head or uncinate process [American Joint Committee on Cancer (AJCC) Stage I-III]. Surgery (pancreaticoduodenectomy) may be performed at M. D. Anderson Cancer Center or prior to referral to M. D. Anderson Cancer Center. Protocol treatment must begin within 12 weeks of surgery.
  2. Postoperative (pre-treatment) computed tomography (CT) scan without evidence of radiographically defineable residual primary/metastatic disease or clinically significant post-surgical changes.
  3. Staging studies completed within three weeks +/- 3 days of protocol registration.
  4. Hemoglobin (Hb) >9.0 g/%, White Blood Count (WBC) >3,000 cells/mm3 (Absolute neutrophil count (ANC)>1,500 cells/mm3), platelets >75,000 cells/mm3.
  5. Postoperative serum calcium (CA) 19-9 < 100.
  6. Performance status: Zubrod 0 or 1.
  7. Creatinine £1.5 mg/dL and calculated or measured creatinine clearance (CrCl) of 60 ml/min or greater by the following formula: Creatinine clearance rate (CrCl) = (140 - age) * Weight (kg) * 0.85 (female) OR * 1.00 (male) 72 * serum creatinine
  8. Patients should have bilateral renal function, as determined on excretory urogram (IVP) or abdominal CT, or ³ 2/3 of one functioning kidney must be able to be shielded from the radiation beam.
  9. No acute infections at the time of therapy initiation.
  10. Women of childbearing potential must agree to practice adequate contraception and to refrain from breast feeding, as specified in the informed consent.
  11. Patients must sign a study-specific consent form, which is attached to this protocol.
  12. Patients with a prior history of non-pancreatic malignancy who are free of disease from their primary cancer may be eligible at the discretion of the study chair.

Exclusion Criteria:

  1. Residual (clinical or CT definable) metastatic or incompletely resected local disease.
  2. Patients with positive peritoneal cytology (for adenocarcinoma) detected at laparotomy for pancreaticoduodenectomy or as part of prior laparoscopic assessment of peritoneal cytology.
  3. Patients with a history of hypersensitivity to interferon alfa-2b.
  4. Patients with significant cardiovascular disease, such as unstable angina or congestive heart failure.
  5. Pregnancy or breastfeeding.
  6. Patients with severe pulmonary disease.
  7. Children under the age of 18 are excluded (as the disease is rare and toxicity profile of this regimen untested in pediatric patients).
  8. Presence or history of severe depression.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00068575
ID02-040, P30CA016672, MDA-ID-02040, CDR0000327752
No
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
  • Schering-Plough
Study Chair: Peter W. Pisters, MD M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP